Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2917-2927

  Assassi, Shervin ^a   Wu, Minghua ^a   Tan, Filemon K ^a   Chang, Jeffrey ^a   Graham, Tiffany A ^a   Furst, Daniel E ^b,d   Khanna, Dinesh ^b,d   Charles, Julio ^a   Ferguson, Emma C ^a   Feghali Bostwick, Carol ^c   Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; STROMELYSIN;

ARTICLE; CLUSTER ANALYSIS; CONFOUNDING VARIABLE; CORRELATION ANALYSIS; DISEASE SEVERITY; FORCED VITAL CAPACITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFLAMMATORY CELL; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE TRAIT; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOPSY; CELL ADHESION; CREST SYNDROME; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; PIPERAZINES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN PHYSIOLOGICAL PHENOMENA; TRANSCRIPTOME;

EID: 84886790538     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38101     Document Type: Article

References (27)

1. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
3. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
4. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
5. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
6. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA,. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783-94.
7. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961-73.
8. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100: 12319-24.
9. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
10. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012; 180: 1080-94.
11. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694-705.
12. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-6.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
14. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87.
15. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis-continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194-200.
16. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
17. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21.
18. T method. Methods 2001; 25: 402-8.
19. Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S,. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008; 35: 2363-71.
20. Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005; 52: 3772-82.
21. Blann AD, Constans J, Carpentier P, Renard M, Satger B, Guerin V, et al. Soluble P selectin in systemic sclerosis: relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease. Thromb Res 2003; 109: 203-6.
22. Patel KD, Moore KL, Nollert MU, McEver RP,. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest 1995; 96: 1887-96.
23. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S,. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30: 231-7.
24. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1038-44.
25. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al, for the Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490-8.
26. Farina G, Lafyatis D, Lemaire R, Lafyatis R,. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
27. Hinchcliff M, Huang CC, Wood TA, Matthew MJ, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979-89.